New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
09:08 EDTZSPHZS Pharma receives notices of allowances from USPTO for ZS-9
ZS Pharma announced that it has received Notices of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9, the company’s product candidate in Phase 3 development for the treatment of hyperkalemia. The 13/371,080 Application describes compositions of matter that include ZS-9 and the 14/036,489 Application covers methods of treating hyperkalemia with compositions described in 13/371,080. The patents to be issued from these applications carry a patent term to at least 2032.
News For ZSPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:26 EDTZSPHBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with Dr. Kosiborod, Cardiologist, St. Luke's Mid-America Heart Institute discuss limitations of current standard of care and innovative new treatments for Hyperkalemia, including ZS Pharma’s ZS-9 and Relypsa’s Patiromer on an Analyst/Industry conference call to be held on April 27 at 11 am.
April 15, 2015
17:16 EDTZSPHZS Pharma's hyperkalemia candidate shows positive data in two publications
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use